Long-term efficacy of tianeptine on alcoholic relapses in non-depressed alcoholic patients. Preliminary results

1993 ◽  
Vol 8 (S2) ◽  
pp. 125s-129s
Author(s):  
JD Favre ◽  
H Lôo ◽  
C Marey ◽  
B Delalleau
Keyword(s):  
Substance Dependence ◽  
Daily Intake ◽  
Term Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Mean Cell Volume ◽  
Preliminary Results ◽  
Long Term Treatment ◽  
Minimum Score

SummaryTianeptine, whose main neurochemical action is to increase 5-HT uptake, significantly decreased alcohol consumption in rats. During a tianeptine long-term treatment study, gamma-GT levels in depressed alcoholic patients decreased, suggesting that this medication could be useful in alcoholism. The role of tianeptine in the prevention of alcoholic relapses is being evaluated in a double-blind placebo-controlled study. Two hundred non-depressed patients satisfying DSM III-R criteria for Psychoactive Substance Dependence (alcohol – daily intake greater than 80 g) will enter the study after alcohol withdrawal. A minimum score of three on the Short-Mast Questionnaire, mean cell volume above 98 f1 and/or gamma-GT more than twice the upper normal value are required. Patients are treated as out-patients and surveyed for 9 months. The maintenance of abstinence is estimated through clinical and laboratory assessments. The alcohol intake is evaluated in patients who relapse. Efficacy is determined secondarily using Clinical Global Impressions Scale, Hopkins Symptom Check List and visual analogue scales. Somatic complaints are collected using AMDP-5. Preliminary results are presented.

scholarly journals Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

2017 ◽  
Vol 69 (3) ◽  
pp. 347-355 ◽  
Author(s):  
Arthur Kavanaugh ◽  
Philip J. Mease ◽  
Andreas M. Reimold ◽  
Hasan Tahir ◽  
Jürgen Rech ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Term Treatment ◽  
Phase Iii ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment

Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study

2004 ◽  
Vol 82 (1) ◽  
pp. 145-148 ◽  
Author(s):  
Vittorio Unfer ◽  
Maria Luisa Casini ◽  
Loredana Costabile ◽  
Marcella Mignosa ◽  
Sandro Gerli ◽  
...  
Keyword(s):  
Term Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment

Metabolic syndrome in patients with schizophrenia receiving long-term treatment with lurasidone, quetiapine XR, or risperidone

2016 ◽  
Vol 33 (S1) ◽  
pp. S105-S105
Author(s):  
J. Newcomer ◽  
M. Tocco ◽  
A. Pikalov ◽  
H. Zheng ◽  
J. Cucchiaro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Antipsychotic Agents ◽  
Term Treatment ◽  
Adult Patients ◽  
Fixed Dose ◽  
Controlled Study ◽  
Double Blind ◽  
Quetiapine Xr ◽  
Long Term Treatment

IntroductionLurasidone has demonstrated low propensity for metabolic disturbance in adult patients with schizophrenia in short-term studies.ObjectivesTo evaluate metabolic syndrome occurrence during long-term lurasidone treatment in patients with schizophrenia.AimsTo compare metabolic syndrome rates with lurasidone versus other antipsychotic agents.MethodsMetabolic syndrome rates (as defined by the US National Cholesterol Education Program-Adult Treatment Panel III) were evaluated in adult patients with schizophrenia treated with lurasidone in 2 long-term, active-controlled studies (quetiapine XR or risperidone). In the quetiapine XR-controlled study, patients completing a 6-week, double-blind, placebo-controlled, fixed-dose trial of lurasidone (74 mg/d or 148 mg/d) or quetiapine XR (600 mg/d) continued on double-blind, flexibly dosed lurasidone (37–148 mg/d) or quetiapine XR (200–800 mg/d) for up to 12 months. In the risperidone-controlled study, patients received double-blind, flexibly dosed lurasidone (37–111 mg/d) or risperidone (2–6 mg/d) for up to 12 months.ResultsAmong patients without metabolic syndrome at baseline in the quetiapine XR-controlled study, 2.4% (2/84) of lurasidone-treated patients and 7.4% (2/27) of quetiapine XR-treated patients developed metabolic syndrome at month 12 (P = NS). Of patients without metabolic syndrome at baseline in the risperidone-controlled study, 10.3% (12/117) and 23.2% (16/69) of lurasidone- and risperidone-treated patients, respectively, developed metabolic syndrome at month 12 (P = 0.02).ConclusionsLong-term treatment with lurasidone was associated with lower rates of metabolic syndrome in patients with schizophrenia compared to treatment with quetiapine XR or risperidone.SupportSunovion Pharmaceuticals Inc.ClinicalTrials.gov identifiersNCT00789698, NCT00641745.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study

1998 ◽  
Vol 115 (5) ◽  
pp. 1072-1078 ◽  
Author(s):  
U TURUNEN ◽  
M FARKKILA ◽  
K HAKALA ◽  
K SEPPALA ◽  
A SIVONEN ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Term Treatment ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment

Effect of Anticholinergics on Tardive Dyskinesia

1984 ◽  
Vol 145 (3) ◽  
pp. 304-310 ◽  
Author(s):  
W. Greil ◽  
H. Haag ◽  
G. Rossnagl ◽  
E. Rüther
Keyword(s):  
Tardive Dyskinesia ◽  
Rating Scales ◽  
Term Treatment ◽  
Controlled Study ◽  
Anticholinergic Medication ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Long Term Treatment ◽  
Schizophrenic Patients

SummaryIn a double-blind, placebo-controlled study, ten chronic schizophrenic patients with pronounced symptoms of tardive dyskinesia (TD) were withdrawn from anticholinergic medication. All patients had previously been under long-term treatment with neuroleptics and anticholinergics for at least two years. The rating-scales used were the AIMS, our own TD Scale, and the Simpson-Angus scale for extra-pyramidal side-effects. The severity of TD decreased significantly in nine patients within two weeks; this improvement, most pronounced in the oral region (P <.001), persisted during a six-week placebo period. There was a slight increase in parkinsonian symptoms (P <.05), which was not a prerequisite for improvement in TD. Hence, discontinuation of anticholinergic medication is a possible therapeutic approach in patients with TD.

Sign in / Sign up

Export Citation Format

Share Document